Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Sponsor
Fudan University
Study ID
NCT06572722
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    atezolizumab adjuvant therapy
  • Nivolumab — DRUG
    nivolumab neoadjuvant therapy
  • Pembrolizumab — DRUG
    pembrolizumab neoadjuvant+adjuvant therapy

Study Details

This trial is a randomized, multicenter, open label phase II clinical study. The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities (atezolizumab adjuvant therapy, nivolumab neoadjuvant therapy, pembrolizumab neoadjuvant+adjuvant therapy) in early-stage resectable NSCLC patients. The enrolled patients are randomly assigned in a 1:1:1 ratio to receive relevant treatment in the three perioperative immunotherapy groups mentioned above, and undergoing short-term pathological efficacy evaluation and long-term prognosis follow-up after surgery.

Key Dates

Start date
Sep 1, 2024
Status verified
Apr 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2029

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
  • Experimental: Nivolumab
  • Experimental: Pembrolizumab

Primary Outcome Measure

Disease-free survival [ Time Frame: 2 years ]

Related Studies